TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

ZOMACTON

SOMATROPIN
Metabolic Approved 1995-05-25

Zomacton (somatropin) is a recombinant human growth hormone used to treat growth failure and short stature in both pediatric and adult populations. In children, it is indicated for growth hormone deficiency, Turner syndrome, idiopathic short stature, SHOX deficiency, and those born small for gestational age who fail to achieve catch-up growth. For adults, the medication serves as a replacement therapy for inadequate endogenous growth hormone secretion. The drug addresses various genetic and developmental conditions that prevent patients from reaching normal height ranges or maintaining metabolic balance.

Source: FDA Label • FERRING

How ZOMACTON Works

Somatropin functions by binding to dimeric growth hormone receptors located on the cell membranes of target tissues. This interaction triggers intracellular signaling that induces the production of growth-dependent proteins, including insulin-like growth factor 1 (IGF-1). These proteins stimulate skeletal growth by promoting the differentiation and proliferation of cells within the growth plates of long bones. Additionally, the drug facilitates linear growth and metabolic regulation by increasing cellular protein synthesis and stimulating hepatic glucose output.

Source: FDA Label
3
Indications
--
Phase 3 Trials
30
Years on Market

Details

Status
Prescription
First Approved
1995-05-25
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

Active Ingredient: SOMATROPIN

ZOMACTON Approval History

Loading approval history...

What ZOMACTON Treats

5 indications

ZOMACTON is approved for 5 conditions since its original approval in 1995. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Growth Hormone Deficiency
  • Turner Syndrome
  • Idiopathic Short Stature
  • Short Stature Homeobox-Containing Gene Deficiency
  • Small for Gestational Age
Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ZOMACTON FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

ZOMACTON is a recombinant human growth hormone indicated for: Pediatric: Treatment of pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone (GH), short stature associated with Turner syndrome, idiopathic short stature (ISS), short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency, and short stature born small for gestational age (SGA) with no catch-up growth by 2 years to 4 years. Adult: Replacement of endogenous GH in adults with GH deficiency 1.1 Pediatric Patients ZOMACTON is indicated for the treatment of pediatr...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.